BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dalcetrapib: Phase IIb data

The double-blind, North American Phase IIb dal-PLAQUE trial in 130 patients with CHD showed that once-daily 600 mg oral dalcetrapib significantly reduced the placebo-corrected change from baseline in total carotid vessel area at 2 years (p=0.041), but non-significantly improved plaque to blood ratio from...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >